HRP20020168A2 - TREATMENT OF MIGRAINE BY THE ADMINISTRATION OF alpha-LIPOIC ACID OR DERIVATIVES THEREOF - Google Patents

TREATMENT OF MIGRAINE BY THE ADMINISTRATION OF alpha-LIPOIC ACID OR DERIVATIVES THEREOF Download PDF

Info

Publication number
HRP20020168A2
HRP20020168A2 HR20020168A HRP20020168A HRP20020168A2 HR P20020168 A2 HRP20020168 A2 HR P20020168A2 HR 20020168 A HR20020168 A HR 20020168A HR P20020168 A HRP20020168 A HR P20020168A HR P20020168 A2 HRP20020168 A2 HR P20020168A2
Authority
HR
Croatia
Prior art keywords
use according
active ingredient
migraine
lipoic acid
dose
Prior art date
Application number
HR20020168A
Other languages
English (en)
Croatian (hr)
Inventor
Jean Schoenen
Juergen Engel
Klaus Wessel
Manfred Peukert
Michael Lobisch
Harald Borbe
Original Assignee
Viatris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh filed Critical Viatris Gmbh
Publication of HRP20020168A2 publication Critical patent/HRP20020168A2/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/48Ergoline derivatives, e.g. lysergic acid, ergotamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HR20020168A 1999-08-30 2002-02-26 TREATMENT OF MIGRAINE BY THE ADMINISTRATION OF alpha-LIPOIC ACID OR DERIVATIVES THEREOF HRP20020168A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19941217A DE19941217A1 (de) 1999-08-30 1999-08-30 Behandlung der Migräne durch Verabreichung von alpha-Liponsäure oder Derivaten derselben
PCT/EP2000/008315 WO2001015693A2 (de) 1999-08-30 2000-08-26 BEHANDLUNG DER MIGRÄNE DURCH VERABREICHUNG VON α-LIPONSÄURE ODER DERIVATEN DERSELBEN

Publications (1)

Publication Number Publication Date
HRP20020168A2 true HRP20020168A2 (en) 2003-06-30

Family

ID=7920152

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020168A HRP20020168A2 (en) 1999-08-30 2002-02-26 TREATMENT OF MIGRAINE BY THE ADMINISTRATION OF alpha-LIPOIC ACID OR DERIVATIVES THEREOF

Country Status (32)

Country Link
US (1) US6251935B1 (cs)
EP (1) EP1207878B1 (cs)
JP (1) JP4773015B2 (cs)
KR (1) KR100624215B1 (cs)
CN (1) CN1170535C (cs)
AT (1) ATE232725T1 (cs)
AU (1) AU781505B2 (cs)
BG (1) BG65735B1 (cs)
BR (1) BR0013651A (cs)
CA (1) CA2382548C (cs)
CZ (1) CZ301789B6 (cs)
DE (2) DE19941217A1 (cs)
DK (1) DK1207878T3 (cs)
EE (1) EE04869B1 (cs)
ES (1) ES2190985T3 (cs)
HK (1) HK1046637A1 (cs)
HR (1) HRP20020168A2 (cs)
HU (1) HU229603B1 (cs)
IL (2) IL148068A0 (cs)
IS (1) IS2214B (cs)
MX (1) MXPA02002246A (cs)
NO (1) NO328692B1 (cs)
NZ (1) NZ517276A (cs)
PL (1) PL200928B1 (cs)
PT (1) PT1207878E (cs)
RS (1) RS50139B (cs)
RU (1) RU2232577C2 (cs)
SK (1) SK286260B6 (cs)
TR (1) TR200200461T2 (cs)
UA (1) UA71031C2 (cs)
WO (1) WO2001015693A2 (cs)
ZA (1) ZA200201637B (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002530396A (ja) * 1998-11-25 2002-09-17 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム スカベンジャー化合物
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
US7943163B2 (en) * 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
KR101493125B1 (ko) 2008-11-24 2015-02-12 세다르스-신나이 메디칼 센터 항산화성 캠토테신 유도체 및 이들의 항산화성 항종양성 나노구체
AU2010247141A1 (en) 2009-05-15 2011-12-15 Redx Pharma Plc Redox drug derivatives
KR100935554B1 (ko) 2009-06-24 2010-01-07 주식회사 셀트리온제약 피페라진 다이티옥트산염 및 이를 포함하는 약제학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU620265A1 (ru) * 1977-02-21 1978-08-25 Центральный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Курортологии И Физиотерапии Способ лечени атеросклероза сосудов головного мозга и гипертонической болезни
EP0326034B1 (de) * 1988-01-28 1992-08-26 Peter Dr. Költringer Kombinationspräparat zur Behandlung von Nervenzell-und Nervenfasererkrankungen und Verletzungen
EP0427247B1 (de) * 1989-11-09 1998-03-11 ASTA Medica Aktiengesellschaft Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure
DE4218572A1 (de) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
DE69331727D1 (de) * 1992-06-30 2002-04-25 Howard K Shapiro Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen
DE4327426A1 (de) * 1993-08-14 1995-02-16 F H Erdaussiebung Gmbh Anbaugerät zum Sieben und Verfüllen von Erdmaterialien
DE4327462A1 (de) * 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen
DE4331168A1 (de) * 1993-09-14 1995-03-16 Carl Heinrich Dr Weischer Kombination von N-Acetyl-p-Aminophenol mit schwefelenthaltenden Carbonsäuren, wie z. B. alpha-Liponsäure und deren Derivate, zur Bekämpfung von Schmerzzuständen
EP0855396A1 (en) * 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Thioctic acid metabolites and methods of use thereof
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
AU8768098A (en) * 1997-08-04 1999-02-22 Christopher J. Berry Method of treating disease using a tocotrienol and alpha-lipoic acid r derivatives or an ester thereof
GB2333757B (en) * 1998-02-03 2001-06-27 Cheung Kwok Chung Sliding platform
AU759467B2 (en) * 1998-04-02 2003-04-17 Avicena Group, Inc. Compositions containing a combination of a creatine compound and a second agent
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos

Also Published As

Publication number Publication date
DK1207878T3 (da) 2003-06-16
IL148068A0 (en) 2002-09-12
CZ301789B6 (cs) 2010-06-23
KR100624215B1 (ko) 2006-09-18
WO2001015693A2 (de) 2001-03-08
CN1170535C (zh) 2004-10-13
EP1207878B1 (de) 2003-02-19
BR0013651A (pt) 2002-05-07
JP2003508438A (ja) 2003-03-04
HUP0203025A3 (en) 2004-12-28
IS2214B (is) 2007-03-15
EP1207878A2 (de) 2002-05-29
EE04869B1 (et) 2007-08-15
AU7279900A (en) 2001-03-26
YU15002A (sh) 2005-03-15
BG65735B1 (bg) 2009-09-30
MXPA02002246A (es) 2003-08-20
PL352741A1 (en) 2003-09-08
NZ517276A (en) 2004-06-25
IL148068A (en) 2007-06-03
PL200928B1 (pl) 2009-02-27
SK286260B6 (sk) 2008-06-06
CN1371280A (zh) 2002-09-25
BG106407A (en) 2002-10-31
TR200200461T2 (tr) 2002-08-21
NO20020917D0 (no) 2002-02-25
DE19941217A1 (de) 2001-03-15
KR20020060168A (ko) 2002-07-16
UA71031C2 (uk) 2004-11-15
EE200200098A (et) 2003-04-15
NO20020917L (no) 2002-02-25
HU229603B1 (en) 2014-02-28
CA2382548A1 (en) 2001-03-08
PT1207878E (pt) 2003-07-31
HUP0203025A2 (hu) 2002-12-28
NO328692B1 (no) 2010-04-26
DE50001301D1 (de) 2003-03-27
SK2902002A3 (en) 2002-09-10
US6251935B1 (en) 2001-06-26
HK1046637A1 (en) 2003-01-24
RS50139B (sr) 2009-03-25
CZ2002655A3 (cs) 2002-07-17
ES2190985T3 (es) 2003-09-01
ATE232725T1 (de) 2003-03-15
JP4773015B2 (ja) 2011-09-14
WO2001015693A3 (de) 2001-12-20
ZA200201637B (en) 2003-01-29
IS6284A (is) 2002-02-26
AU781505B2 (en) 2005-05-26
RU2232577C2 (ru) 2004-07-20
CA2382548C (en) 2007-07-03

Similar Documents

Publication Publication Date Title
US20220378731A1 (en) Composition For Treating Tauopathy In The Brain, Brain Stem and Spinal Column
CA2382548C (en) Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof
US8642639B2 (en) Formulation for L-tryptophane comprising carbidopa/benserazide
US20070292535A1 (en) Strontium compositions and methods of treating arthritic and or osteoporitic conditions
CA2836854C (en) Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration
US20230364043A1 (en) C5 ketone compositions and related methods for therapeutic and performance supplementation
US20240074996A1 (en) C5 ketone compositions and related methods for treating metabolic dysfunction
CA2696918C (fr) Compose pour son utilisation dans le traitement des neuropathies peripheriques
Fitzpatrick Melatonin in health and disease
US20160106708A1 (en) Use of antioxidants for the treatment of cognitive and behavioural disorders in individuals with fragile x syndrome
MX2011013989A (es) Combinacion farmaceutica.
JPH0449235A (ja) 痴呆治療剤
WO2012042128A1 (fr) Composition pharmaceutique comprenant de la memantine et de la vitamine d pour le traitement de la maladie d 1 alzheimer

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: VIATRIS GMBH & CO. KG, DE

ODRP Renewal fee for the maintenance of a patent

Payment date: 20050729

Year of fee payment: 6

ODBI Application refused